The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in @entity1 with XXXX .

@entity1 @entity5 @entity3 @entity787
PURPOSE: The purpose of this study was to evaluate the role of @entity787 after neoadjuvant chemoradiotherapy in @entity1 with @entity5 . METHODS: This study involved 109 @entity1 with @entity5 who were treated with preoperative chemoradiotherapy and curative resection. Preoperative serum @entity787 levels were measured twice, before chemoradiotherapy administration and 4 weeks after chemoradiotherapy. Surgery was performed 6 to 9 weeks after neoadjuvant chemoradiotherapy. RESULTS: The 3-year disease-free survival rate was 85.0%. On univariate analysis, prechemoradiotherapy @entity787 level, postchemoradiotherapy @entity787 level, @entity5 regression grade, ypT, ypN, circumferential resection margin, lymphatic invasion, @entity3 , and perineural invasion were associated with disease-free survival. Based on univariate analysis (group 1: prechemoradiotherapy @entity787  <= 3.5; group 2: prechemoradiotherapy @entity787 > 3.5, postchemoradiotherapy @entity787  <= 2.7; group 3: prechemoradiotherapy @entity787 >3.5, postchemoradiotherapy @entity787 > 2.7), we categorized @entity1 into 3 groups according to their pre- and postchemoradiotherapy @entity787 levels (ng/mL). The 3-year disease-free survival rate was significantly better in groups 1 and 2 (94.7% and 88.0%) than in group 3 (52.6%, P < .001). On multivariate analysis, @entity5 regression grade (P = .036), ypN (P = .036), and @entity787 groups (P = .022) were identified as independent prognostic factors for disease-free survival. Furthermore, postchemoradiotherapy @entity787  <= 2.7 ng/mL was an independent predictor of good @entity5 regression (P = .001), ypT0 to 2 (P = .002), and ypN0 (P = .001). CONCLUSIONS: Combined pre- and postchemoradiotherapy @entity787 levels could be useful as a prognostic factor for disease-free survival in @entity1 with @entity5 who undergo treatment with neoadjuvant chemoradiotherapy and curative resection. Postchemoradiotherapy @entity787 may be helpful in a selection of @entity1 who want more conservative surgery after chemoradiotherapy.
